-
Experienced Intellectual Property Transactional Attorney
Farah counsels clients with respect to the structuring and negotiation of a wide range of agreements, including strategic alliances, joint ventures, incubator structures, options, and build-to-buy arrangements.
-
A Focus on Scientific Clients
Her clients are primarily based in the pharmaceutical, biotechnology, medical device, and diagnostic industries.
-
Regulatory Expertise
Farah advises her life sciences clients on a variety of FDA regulatory and healthcare issues, in the context of their business transactions.
Farah Gerdes founded and leads the technology transactions practice in Wilson Sonsini Goodrich & Rosati's Boston office, where she focuses on the representation of pharmaceutical, biotechnology, medical device, and diagnostic companies in complex collaboration and partnering transactions. She advises numerous domestic and international, public and private life sciences companies on business transactions related to the discovery, development, supply, and commercialization of life sciences products and technologies. She counsels her clients with respect to the structuring and negotiation of a wide range of agreements, including strategic alliances, joint ventures, incubator structures, options, and build-to-buy arrangements, each designed to maximize the value of their assets. In addition, Farah helps companies with a broad range of other transactions, including technology and asset acquisition, license, discovery, research, development (including clinical development), manufacture and supply, promotion, marketing, distribution, and services agreements. She works closely with her clients in setting strategic direction and structuring and negotiating mission-critical business arrangements.
As a complement to her transactional IP practice, Farah advises her life sciences clients on a variety of FDA regulatory and healthcare issues, in the context of their business transactions.
Farah Gerdes founded and leads the technology transactions practice in Wilson Sonsini Goodrich & Rosati's Boston office, where she focuses on the representation of pharmaceutical, biotechnology, medical device, and diagnostic companies in complex collaboration and partnering transactions. She advises numerous domestic and international, public and private life sciences companies on business transactions related to the discovery, development, supply, and commercialization of life sciences products and technologies. She counsels her clients with respect to the structuring and negotiation of a wide range of agreements, including strategic alliances, joint ventures, incubator structures, options, and build-to-buy arrangements, each designed to maximize the value of their assets. In addition, Farah helps companies with a broad range of other transactions, including technology and asset acquisition, license, discovery, research, development (including clinical development), manufacture and supply, promotion, marketing, distribution, and services agreements. She works closely with her clients in setting strategic direction and structuring and negotiating mission-critical business arrangements.
As a complement to her transactional IP practice, Farah advises her life sciences clients on a variety of FDA regulatory and healthcare issues, in the context of their business transactions.
- J.D., University of Chicago Law School, 2005Editor, Chicago Journal of International Law; Editor in Chief, The Phoenix
- M.A., New York University, 1999
- B.A., Williams College, 1996
- Selected for inclusion in Lawdragon's 2025 500 Leading Dealmakers in America guide
- Named “Partner of the Year” winner in Law.com’s 2024 New England Legal Awards
- Named a “2023 Top Women of Law” honoree by Massachusetts Lawyers Weekly
- Named to the 2011, 2012, 2013, 2014, and 2015 editions of the "Rising Stars" list published by Northern California Super Lawyers
- State Bar of California
- State Bar of Massachusetts
- J.D., University of Chicago Law School, 2005Editor, Chicago Journal of International Law; Editor in Chief, The Phoenix
- M.A., New York University, 1999
- B.A., Williams College, 1996
- Selected for inclusion in Lawdragon's 2025 500 Leading Dealmakers in America guide
- Named “Partner of the Year” winner in Law.com’s 2024 New England Legal Awards
- Named a “2023 Top Women of Law” honoree by Massachusetts Lawyers Weekly
- Named to the 2011, 2012, 2013, 2014, and 2015 editions of the "Rising Stars" list published by Northern California Super Lawyers
- State Bar of California
- State Bar of Massachusetts
Recent Illustrative Representations
- Recursion Pharmaceuticals in various partnering deals and acquisitions, including with Takeda, Bayer and Roche/Genentech, Cyclica, Valence, and ExScientia
- Zymeworks in its collaboration and license arrangements with Merck, Eli Lilly, Glaxo SmithKline, Celgene, Daichii Sankyo, Janssen, LEO Pharma, BeiGene, CytomX Therapeutics, Jazz, and others to design, develop, and commercialize proprietary bi-specific antibodies and antibody-drug conjugates
- Genevant in various partnering deals for its LNP delivery technology, including with Korro Bio, Novo Nordisk, Tome Biosciences, Gritstone Bio, and Repair Biotechnologies
- Ochre Bio in its data license agreement with GSK
- C4 Therapeutics in its license and research collaboration agreements with Merck KGaA and Merck
- Nvelop Therapeutics in its license agreements with the Broad Institute and Mass General Hospital
- Ultragenyx in its license agreement with Regeneron to commercialize Evinacumab outside of the United States
- Tango Therapeutics in its original and expanded strategic collaborations with Gilead Sciences
- Theravance Biopharma in its global license agreement with Pfizer and its collaboration arrangement with Janssen
- Rheos Medicines in its worldwide exclusive collaboration, option, and license agreement with Roche
- NanoString Technologies in companion diagnostic collaborations with Celgene, Medivation, Astellas, Merck, Lam Research, and others
- NanoString in its asset sale of its companion diagnostics business to Veracyte
- Neon Therapeutics in its clinical trial collaboration and supply agreement with Merck
- GRAIL in its research collaborations with Merck, Bristol-Myers Squibb Company, and Janssen
- Mylan in various biosimilar, specialty pharma, and generic licensing and asset purchase deals, including with Theravance, Momenta, and Fujifilm Kyowa Kirin Biologics
- ForSight VISION4 in its collaboration arrangement with and subsequent acquisition by Roche
- Neurotechnology Innovations Translator and its spin-out companies in unique grant and option arrangements
Recent Illustrative Representations
- Recursion Pharmaceuticals in various partnering deals and acquisitions, including with Takeda, Bayer and Roche/Genentech, Cyclica, Valence, and ExScientia
- Zymeworks in its collaboration and license arrangements with Merck, Eli Lilly, Glaxo SmithKline, Celgene, Daichii Sankyo, Janssen, LEO Pharma, BeiGene, CytomX Therapeutics, Jazz, and others to design, develop, and commercialize proprietary bi-specific antibodies and antibody-drug conjugates
- Genevant in various partnering deals for its LNP delivery technology, including with Korro Bio, Novo Nordisk, Tome Biosciences, Gritstone Bio, and Repair Biotechnologies
- Ochre Bio in its data license agreement with GSK
- C4 Therapeutics in its license and research collaboration agreements with Merck KGaA and Merck
- Nvelop Therapeutics in its license agreements with the Broad Institute and Mass General Hospital
- Ultragenyx in its license agreement with Regeneron to commercialize Evinacumab outside of the United States
- Tango Therapeutics in its original and expanded strategic collaborations with Gilead Sciences
- Theravance Biopharma in its global license agreement with Pfizer and its collaboration arrangement with Janssen
- Rheos Medicines in its worldwide exclusive collaboration, option, and license agreement with Roche
- NanoString Technologies in companion diagnostic collaborations with Celgene, Medivation, Astellas, Merck, Lam Research, and others
- NanoString in its asset sale of its companion diagnostics business to Veracyte
- Neon Therapeutics in its clinical trial collaboration and supply agreement with Merck
- GRAIL in its research collaborations with Merck, Bristol-Myers Squibb Company, and Janssen
- Mylan in various biosimilar, specialty pharma, and generic licensing and asset purchase deals, including with Theravance, Momenta, and Fujifilm Kyowa Kirin Biologics
- ForSight VISION4 in its collaboration arrangement with and subsequent acquisition by Roche
- Neurotechnology Innovations Translator and its spin-out companies in unique grant and option arrangements
- Privacy Policy
- Terms of Use
- Accessibility